ATE383170T1 - Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c - Google Patents

Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c

Info

Publication number
ATE383170T1
ATE383170T1 AT02759107T AT02759107T ATE383170T1 AT E383170 T1 ATE383170 T1 AT E383170T1 AT 02759107 T AT02759107 T AT 02759107T AT 02759107 T AT02759107 T AT 02759107T AT E383170 T1 ATE383170 T1 AT E383170T1
Authority
AT
Austria
Prior art keywords
infection
cell
inhibit
hcv
hcv infection
Prior art date
Application number
AT02759107T
Other languages
English (en)
Inventor
William Olson
Paul Maddon
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Application granted granted Critical
Publication of ATE383170T1 publication Critical patent/ATE383170T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02759107T 2001-06-26 2002-06-26 Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c ATE383170T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/891,894 US20030013081A1 (en) 2001-06-26 2001-06-26 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection

Publications (1)

Publication Number Publication Date
ATE383170T1 true ATE383170T1 (de) 2008-01-15

Family

ID=25399013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02759107T ATE383170T1 (de) 2001-06-26 2002-06-26 Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c

Country Status (8)

Country Link
US (1) US20030013081A1 (de)
EP (2) EP1411980B1 (de)
JP (1) JP2005521628A (de)
AT (1) ATE383170T1 (de)
CA (1) CA2452049A1 (de)
DE (1) DE60224541T2 (de)
ES (1) ES2296985T3 (de)
WO (1) WO2003000024A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4322504B2 (ja) * 2000-12-21 2009-09-02 スチヒティング カソリーケ ユニバーシテット， ラッドボウド ユニバーシティ ネイメヘン メディカル センター 肝臓およびリンパ節中の類洞内皮細胞上において、新規なｉｃａｍ−３結合レセプターの結合活性を調節するための方法
US7022323B2 (en) * 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
WO2004026326A2 (en) * 2002-09-20 2004-04-01 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
US20050281828A1 (en) * 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
NZ542134A (en) * 2003-03-04 2009-06-26 Alexion Pharma Inc Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
CN113150076B (zh) * 2021-03-03 2022-05-31 天津医科大学 环五肽的合成方法及其在抗丙肝药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3752347T2 (de) 1986-05-20 2002-09-26 The General Hospital Corp., Boston Verfahren zur pharmakokinetischen Studie der Insulin-Expression mit nicht-menschlichem Transgen-Säugetier
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
NZ243908A (en) 1991-08-16 1994-12-22 Beth Israel Hospital Assn Mutant l3t4 protein which facilitates hiv infection; transgenic mouse
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US5912411A (en) 1993-06-14 1999-06-15 University Of Heidelberg Mice transgenic for a tetracycline-inducible transcriptional activator
WO1995025954A1 (en) 1994-03-18 1995-09-28 Japan Poliomyelitis Research Institute Method of testing neurotoxicity of poliovirus vaccine
EP0690452A3 (de) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Elektrisch löschbarer Speicher und Löschverfahren
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US6018098A (en) 1995-06-16 2000-01-25 Thomas Jefferson University In vivo and in vitro model of cutaneous photoaging
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
US5894078A (en) 1996-02-26 1999-04-13 Advanced Bioconcept, Inc. Transgenic mouse expressing C-100 app
US6025539A (en) 1996-04-09 2000-02-15 Mayo Foundation For Medical Education And Research IL-5 transgenic mouse
US5981829A (en) 1996-05-08 1999-11-09 Uab Research Foundation ΔNur77 transgenic mouse
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
DE69841322D1 (de) 1997-10-06 2010-01-07 Novartis Vaccines & Diagnostic Hepatitis c rezeptorprotein cd81
EP1046651A1 (de) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Zusammensetzungen und Verfahren zur Modulierung des interaktion zwischen dendritischer und T-zellen

Also Published As

Publication number Publication date
WO2003000024A3 (en) 2003-07-31
EP1411980B1 (de) 2008-01-09
DE60224541D1 (de) 2008-02-21
EP1411980A2 (de) 2004-04-28
ES2296985T3 (es) 2008-05-01
WO2003000024A2 (en) 2003-01-03
JP2005521628A (ja) 2005-07-21
DE60224541T2 (de) 2008-12-24
EP1946770A1 (de) 2008-07-23
US20030013081A1 (en) 2003-01-16
EP1411980A4 (de) 2005-06-29
CA2452049A1 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
ATE553201T1 (de) Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismittel
EA200300023A1 (ru) 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ
EA200700243A1 (ru) Способы лечения гепатита с
DE69435155D1 (de) Zusuammensetzungen zur Behandlung von Krebs mittels Viren
DE69434931D1 (de) Methode zur selektiven inaktivierung der viralen replication
CO5580797A2 (es) Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos
DK0637342T3 (da) Fremgangsmåde til typebestemmelse af HCV-isolater
BR0305259A (pt) Inibidores de hcv ns5b polimerase
ATE318176T1 (de) Verfahren zur entfernung von hiv und anderen viren aus blut
DE602005027590D1 (de) Transparente glaslaminate
AR063315A2 (es) Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus
WO1998045415B1 (en) Method for inactivating a virus
DK0713495T3 (da) Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner
DE69434117D1 (de) Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien
WO2002055025A3 (en) Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
BR9304352A (pt) Processo para a preparaçao de catalisador do tipo ziegler-natta com suporte granular e catalisador
ATE383170T1 (de) Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c
ATE309540T1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
ATE481101T1 (de) Verfahren zur behandlung von angstzuständen
DE69433400D1 (de) Neue proteine von parasitischen würmern
BR0311223A (pt) Método para o uso de derivados de piranindol para tratar infecção pelo vìrus da hepatite c
WO2003040726A3 (en) Screening for hepatitis c virus entry inhibitors
SG132690A1 (en) Methods and compounds for altering the load of hepatitis virus
SE0302652D0 (sv) Attachment of cells to surfaces

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties